Since the commencement of COVID-19 vaccines, there has been an unprecedented rise in the deaths of young people between 2021 and 2022 from rapidly metastasizing and terminal cancers, according to data from the UK’s Office for National Statistics. While we would expect that the UK government and their “health experts” who were so concerned about our health in 2020 would have conducted an urgent inquiry into the shocking data, alas no, they have remained predictably silent.
An analysis of this data, however, has been conducted by former former BlackRock portfolio manager and data analyst, Ed Dowd and assembled by Carlos Alegria, one of Dowd’s partners, in his Humanity Projects. Their study of excess deaths in the U.K. and the U.S. using government and insurance industry data has shown that there has been “2 or 3 times the normal rate of cancer.” according to Dowd.
An analysis of U.K. government data shows an unprecedented increase in cancer deaths among 15- to 44-year-olds following the rollout of COVID-19 vaccines, according to a new report by data analyst Edward Dowd. The report has prompted renewed calls for further investigation.
Teenagers and young people in their 20s, 30s and 40s in the U.K. are dying from rapidly metastasizing and terminal cancers at an unprecedented rate since mass COVID-19 vaccination began, according to a new analysis by Edward Dowd.
The 45-page report by Dowd, a former Wall Street hedge fund manager and author of “‘Cause Unknown’: The Epidemic of Sudden Deaths in 2021 and 2022,” alarmed some oncologists who characterized it as a sharp reversal of decades of mortality data.
Dowd based his analysis on readily available government statistics from the U.K.’s Office for National Statistics.
In an interview with The Defender, Dowd said he and his research partners, who include a handful of high-level scientists, data analysts and financial experts, examined all International Classification of Diseases, 10th Revision, (ICD-10) codes for cause of death in the U.K. in the study period of 2010-2022 to investigate trends in malignant neoplasms (C00 to C99 codes).
ICD-10 codes are the international physicians’ classification of diagnosis, symptom and procedure for claim processing set by the World Health Organization (WHO). A malignant neoplasm is a cancerous tumor.
Dowd said his research team noticed a striking pattern: While almost all deaths among older people in 2021 and 2022 in Wales and England had been coded, 8% of deaths among 15- to 44-year-olds in 2021, and 30% of deaths in that age group in 2022, hadn’t yet been coded.
“When you die in a hospital, you leave a trail of life and death with indications of what led to the death,” he said. “When a young person dies at the wheel of a car, walking down the street or in their sleep, there’s an investigation” that consumes time to assign the cause of death.
Dowd said the missing codes are “indicative of the problem” of excess deaths among young people.
But even with the caveat of missing codes, he said, the remaining 92% of coded deaths in 2021 and 70% of coded deaths in 2022 revealed “a strong signal of cancer deaths in the young. We show a large increase in mortality due to malignant neoplasms that started in 2021 and accelerated substantially in 2022.
“The increase in excess deaths in 2022 is highly statistically significant (extreme event),” Dowd wrote in his report. “The results indicate that from late 2021 a novel phenomenon leading to increased malignant neoplasm deaths appears to be present in individuals aged 15 to 44 in the UK.”
The study’s results in the rate of cancer deaths above the historic norm in 2022 for ages 15-44 in the U.K. included:
A 28% rise in fatal breast cancer rates in women.
An 80% increase in pancreatic cancer deaths among women and a 60% increase among men.
A 55% increase among men in colon cancer deaths and a 41% increase in women.
A 120% increase in fatal melanomas among men and a 35% increase in women.
A 35% increase in brain cancer deaths among men and a 12% rise in women.
A 60% increase in cancer death rates among men in cancers “without site specification” and a 55% increase among women.